Biocon Stock

Stocks to Watch: Indigo, Infosys, Blue Star, Biocon, Britannia, 63 Moons

Share market today: IndiGo Airlines has emerged as the world's second fastest-growing airline in terms of seat capacity, with a 10.1 per cent increase in 2024

Here's why Biocon share price popped 3% in trade on March 5; details here

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA

Stocks to Watch, March 5: Adani Wilmar, Coforge, Biocon, Ola Electric, RVNL

Biocon: The company's subsidiary, Biocon Pharma, has received USFDA approvals for Lenalidomide capsules and Dasatinib tablets, and tentative approval for Rivaroxaban tablets

Biocon share price up 2% as arm launches Yesintek in US; check details here

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available to patients in US

Here's why Biocon share price gained 4% despite fall in profits in Q3

Biocon share price gained 3.82 per cent at Rs 370.80 a piece on the BSE in Friday's intraday trade

Biocon gains 3% after board to mull raising funds via commercial papers

Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday's intraday trade

Chandan Taparia of MOFSL recommends buying these stocks on January 21

Bajaj Finserv stock has broken out of a flag and pole pattern on the daily chart with a large bodied bullish candle suggesting strength. The RSI indicator is rising which confirms the upward momentum

Ajit Mishra of Religare Broking picks Biocon, Marico as stocks to buy today

Stocks to Buy Today: Ajit Mishra of Religare Broking suggests buying Biocon shares and Marico shares. He also suggests shorting Asian Paints shares

Chandan Taparia of MOFSL recommends buying these 3 stocks on January 15

Stocks to buy today, Jan 15: Bajaj Finance share price is on the verge of a breakout from a flag and pole pattern on the daily chart with higher-than-average buying volumes

Biocon, Marico among 5 mid-, small-cap stocks holding fort in a weak market

The overall market trend has been negative with over 60% of the Nifty Mid- and Small-Cap stocks now trading below the long-term moving averages; however, these 5 stocks continue to buck the trend.

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions

Biocon shares gain 4% after USFDA gives VAI tag to its Malaysia unit

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru facility in Malaysia was classified as "Voluntary Action Indicated"

Biocon rises 3% after its arm gets US FDA nod for psoriasis drug YESINTEK

Biocon Biologics Ltd had previously notified on February 29, 2024, that the company had entered into a settlement and licensing agreement with Janssen

Biocon share jumps 6% on USFDA's 'VAI' tag to Bengaluru facility; details

The surge in Biocon share price came after the company announced that United States Food and Drug Administration (USFDA) has classified Biocon Biologics' Biocon Park Site in Bengaluru as VAI

Biocon shares tank 6% after reporting net loss of Rs 16 cr in Q2FY25

Shares of pharmaceutical company Biocon tanked 5.96 per cent at Rs 301.65 a piece on the BSE

Stocks to Watch, Oct 31: Biocon, L&T, Tata Power, RVNL, Zydus Wellness

Stocks to Watch, October 31, 2024: L&T's revenue up 20.63 per cent at Rs 61,554 crore versus Rs 51,024 crore. Ebitda up 12.94 per cent at Rs 6,362 crore versus Rs 5,633 crore

Biocon Q2 FY25 results: Net profit declines 84% to Rs 27.1 crore

Revenue driven by gains from US Oncology and Insulins franchises

Biocon, PFC, Chambal Fert; top picks by Ajit Mishra of Religare Broking

The pharma sector is showing notable resilience, with Biocon taking the lead. The stock has broken out from a bullish rectangle pattern, accompanied by a strong surge in volumes

Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure

Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure. Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The medicine is also used to treat paediatric patients over the age of one year. The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.

Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24